340B program flexibilities will continue under the eighth 90-day extension of the COVID-19 national public health emergency (PHE) late last week.
U.S. Health and Human Services (HHS) Secretary Xavier Becerra renewed the PHE on Friday, Jan. 14.
…
Year: 2022
Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
According to late-day email messages from BMS to 340B
…
The National Association of Community Health Centers said in an email to its contacts yesterday that Tom Van Coverden, 74, hired by NACHC in 1975 and its leader for decades, has taken leave and been replaced by an interim president
…
The 340B Coalition, citing the ongoing COVID-19 pandemic, decided Tuesday to give registrants for its upcoming Jan. 31 to Feb. 2 winter conference in San Diego, Calif., the option of attending in person or remotely via an online portal.
Apexus,
…
Bills have been filed in at least five state legislatures to protect 340B covered entities and their contract pharmacies from discrimination by pharmacy benefit managers (PBMs).
Sixteen states have enacted one or more such laws since 2019, according to
…
The Centers for Medicare & Medicaid Services (CMS) yesterday proposed changing Medicare Part D rules to curb plan sponsors and pharmacy benefit managers’ skyrocketing use of direct and indirect renumeration fees (DIR)—PBMs’ controversial practice of clawing back drug payments to
…
SPONSORED CONTENT
Each year, Visante publishes its list of the top 10 issues facing hospital and health system pharmacy. In 2022, many challenges derive from the pandemic but also present opportunities for leaders to implement new solutions that will drive stronger performance in the future.
- The Pandemic
With a second
…
More than half (52%) of the $81 billion that U.S. pharmacies and health care providers collected in 2020 in reimbursement from payers for brand-name prescription drugs came through pharmacy and provider participation in the 340B program, up from 14% of
…
New York state and Virginia health centers on Friday asked a federal district judge to deny four insulin and diabetes drug manufacturers’ motion to dismiss the health centers’ antitrust class action over the companies’ denials of 340B pricing when covered
…